Generation of immunogenic and tolerogenic clinical-grade dendritic cells
Generation of immunogenic and tolerogenic clinical-grade dendritic cells
复制标题
DOI：
10.1007/s12026-011-8255-5
复制
发表时间：
2011-12-01
影响因子：
4.4
通讯作者：
Rostami, Abdolmohamad
中科院分区：
文献类型：
--
作者：
Kalantari, Tahereh;Kamali-Sarvestani, Eskandar;Rostami, Abdolmohamad
树突状细胞（DC）的免疫疗法已在离体操作后具有免疫原性或耐受性，已在疾病治疗的临床试验中进行了测试。 DC 是免疫系统的哨兵，在暴露于抗原或炎症信号并与效应 CD4(+) T 细胞相互作用后，表达高水平的共刺激分子和细胞因子。共刺激分子或细胞因子的上调可促进免疫 DC，而下调则产生耐受性 DC (TDC)，从而诱导 T 调节细胞 (Treg) 和耐受状态。免疫原性DC用于治疗HIV-1和癌症等传染病，而耐受性DC用于治疗各种自身免疫性疾病和移植。 DC疫苗接种仍处于早期阶段，主要需要改进监测检测的质量控制，以产生临床级的DC产品，并在未来的临床试验中评估DC疫苗接种的效果。在这里，我们回顾了最近在 DC 生成和监测方法方面的工作，以使用免疫原性或耐受性 DC 进行基于 DC 的试验。
Immunotherapy with dendritic cells (DCs), which have been manipulated ex vivo to become immunogenic or tolerogenic, has been tested in clinical trials for disease therapy. DCs are sentinels of the immune system, which after exposure to antigenic or inflammatory signals and crosstalk with effector CD4(+) T cells express high levels of costimulatory molecules and cytokines. Upregulation of either costimulatory molecules or cytokines promotes immunologic DCs, whereas their downregulation generates tolerogenic DCs (TDCs), which induce T regulatory cells (Tregs) and a state of tolerance. Immunogenic DCs are used for the therapy of infectious diseases such as HIV-1 and cancer, whereas tolerogenic DCs are used in treating various autoimmune diseases and in transplantation. DC vaccination is still at an early stage, and improvements are mainly needed in quality control of monitoring assays to generate clinical-grade DC products and to assess the effect of DC vaccination in future clinical trials. Here, we review the recent work in DC generation and monitoring approaches for DC-based trials with immunogenic or tolerogenic DCs.